Solventum Deep Value Investment Research

Is Revenue Stable and Predictable? Demand is generally stable. U.S. national health expenditure reached $5.3 trillion in 2024, accounting for 18.0% of GDP; chronic disease remains a major driver of healthcare spending; global aging also continues to push healthcare demand higher. For Solventum, this means wound care, infection prevention, surgical support, dental restoration, and healthcare administrative-efficiency software all have a long-term demand base. On the other hand, this is not a "utility-like" business: hospital budgets, insurance reimbursement, procurement consolidation, product-refresh cycles, and software replacement can all affect short- and medium-term performance.

Cost Structure and Dependencies. The biggest near-term issue in this business is not demand, but cost and execution. The company clearly disclosed that the 2025 increase in product-cost ratio reflected the impact of about $55 million in new tariffs, the full-year impact of obtaining inventory from 3M as primary supplier and under transition manufacturing agreements, and higher logistics costs. The company also disclosed that transition service, manufacturing, R&D master service, and supply agreements with 3M remain important; if 3M fails to perform, Solventum could face short- and long-term operating disruptions. The positive side is that customer concentration is low: in 2025, no customer accounted for more than 10% of revenue or accounts receivable.

Is This an Easy Business to Understand? From the perspective of products and value chain, yes, it is far easier to understand than many biotechnology companies: it does not sell products whose value depends on betting on the outcome of a single drug-development program, but products and software used daily in the healthcare system with relatively clear payment logic. The difficulty is that it is not a "simple company". It is a portfolio assembled from multiple sub-industries: wound care, surgical infection prevention and control, dental materials, and healthcare IT all have different competitive logic, so valuation cannot rely on a single framework. In addition, it is a spin-off company, and historical financial statements before 2024 have 3M carve-out characteristics. Management itself also warns that pre-spin financial statements may not represent the future performance of the independent company.

If the Stock Market Closed for Five Years, Would I Be Willing to Hold It? My answer is: I would be willing to own the "core assets" of this business, but I would not be willing to hold a heavy full stock position at the current price before cash flow repair has been proven. The underlying industry is a good industry, but the company is currently still a "transition asset in a good industry," not a fully polished long-term compounding machine.

Business Understandability Score: 4/5.

Industry and Competitive Landscape. From the industry lifecycle perspective, Solventum is in structural growth tracks within mature industries: traditional MedSurg and dental are more mature, with growth usually tied to procedure volume, product refresh, price/mix optimization; HIS is more structurally growing, because the healthcare system is still pursuing administrative simplification, revenue-cycle efficiency, and clinical-productivity improvement. The main competitors listed by the company include Smith+Nephew, Mölnlycke, Coloplast, Convatec, BD, ICU Medical, Cardinal Health, and Steris in MedSurg; Dentsply Sirona, Envista, Straumann, Ivoclar, and Align in Dental; and Optum, Microsoft/Nuance, Epic, Oracle/Cerner, Waystar, and a group of software start-ups in HIS. In other words, this is an industry with intense competition but decent demand.

Industry Attractiveness Score: 3/5. I would define Solventum's industry as: "a good industry, but not an easy-money industry; a good track, but not an automatic high-moat business." Hospital and dental demand certainly exists over the long term, but there are many suppliers, regulation is strict, product iteration and channel relationships matter, and the profit pool is not naturally easy to monopolize.

Moat and Management

Moat Assessment. Solventum has a moat, but its strength is moderate and not exceptionally deep.

On the positive side, it has several real advantages. First is brand and clinical trust: the company says it owns a broad, well-known portfolio of brands used by customers for a long time, and more than 70 years of history have created customer relationships and clinical acceptance. Second is switching cost: when hospitals change wound-care protocols, infection-prevention consumables, coding software, or speech-documentation systems, this often involves clinical workflows, training, compliance, and IT integration. It does not switch as easily as a consumer product. Third is regulatory and manufacturing know-how: medical consumables, devices, and software all need to pass regulatory, quality-system, and clinical-validation thresholds. Fourth is channel and installed base: HIS adoption and the leased-equipment network provide some renewal and maintenance stickiness.

On the negative side, it has almost no network effects, and its data advantage is weaker than the strongest software-platform companies. The company itself also states clearly that although intellectual property as a whole is important, no single IP asset is decisive to the overall business. What really matters is understanding customer needs, technical capability, and manufacturing know-how. This means it is more like a company with an "operating moat plus embedded clinical position," rather than a company that locks up an industry through a single patent.

Is the Moat Widening, Stable, or Narrowing? My judgment is: slightly narrowing in the short term, with a chance to return to stability over the long term. The reason is simple: before the spin-off, it benefited from 3M's brand, scale, systems, and internal synergies; after the spin-off, the company itself acknowledges the loss of benefits from 3M brand recognition, while independent operation brings additional cost and complexity. In other words, Solventum is not "getting stronger from zero"; it first went through a moat reconstruction. If supply-chain migration, brand independence, and organizational restructuring are completed smoothly in 2026-2028, the moat can return to stability. If execution disappoints, the moat may continue to be eroded.

Pricing Power and Inflation Resistance. The company has some but limited pricing power. In 2025, the HIS segment's margin improvement partly came from price, product mix, and lower external licensing expense. In Q1 2026, the company also disclosed that gross-margin improvement came from project savings, mix, and operating improvement, while still being dragged down by tariffs and inflation. This shows it can partly pass through costs, but it is not the kind of super brand that can raise prices painlessly in a high-inflation environment.

Can It Stay Profitable in a Downturn? The answer is basically "likely profitable, but cash flow may not look good." In 2024, despite a significant increase in separation costs and the initial launch of independent operations, the company still generated positive net income and $1.185 billion of operating cash flow; in 2025, although free cash flow turned to negative $10 million, this was more due to transition and transaction factors than demand collapse. GAAP net income remained positive in Q1 2026, but operating cash flow was negative, with seasonality and transition expenses still obvious.

Moat Strength Score: 3/5.

Management and Capital Allocation. Bryan Hanson has real medical-device industry experience: before becoming Solventum CEO, he served as CEO of 3M's healthcare business; before that, he served as CEO of Zimmer Biomet and held senior roles at Medtronic and Covidien. In terms of resume, he is not a "finance-type manager temporarily assigned from an industrial conglomerate," but someone with industry operating experience. The board also has healthcare, finance, spin-off, and M&A experience.

The governance framework is broadly acceptable: the company has a clawback policy, insider trading windows and 10b5-1 pre-clearance procedures, prohibits executives and directors from hedging, short selling, margin-stock holding, and pledging, and has clear executive share-ownership requirements: the CEO at 6 times base salary, and other executive leadership team members at 3 times base salary. The company disclosed that as of the end of 2025, executives and directors had met the ownership requirements.

But I would keep two reservations. First, the absolute value of real insider ownership is not high: as of March 19, 2026, Bryan Hanson directly beneficially owned about 123,910 shares, and all directors and executive officers as a group owned about 287,500 shares, with another about 125,730 shares acquirable within 60 days. In total, this was still below 1% of shares outstanding. That means the interest alignment exists, but is not especially strong. Second, the company disclosed that CEO Bryan Hanson's in-law Doug Jones joined Solventum in 2024 and served as head of MedSurg North America sales, with the process approved by the governance committee. This is not a serious governance failure, but I would view it as a minor yellow flag that needs continued observation.

Is Capital Allocation Rational? Since becoming independent, management's capital allocation has generally been rational rather than aggressive. The most important step was selling the Purification & Filtration business in 2025 for about $4.0 billion in cash and using the proceeds mainly for deleveraging: in 2025, the company repaid $2.0 billion of senior notes through tender offers, and repaid an $870 million three-year term loan and a $200 million eighteen-month term loan. At the same time, the company completed the acquisition of Acera Surgical in 2025 for total consideration of $776 million to expand its wound-care assets; then the board approved a $1.0 billion repurchase authorization, and in Q1 2026 repurchased about 922,600 shares for $67 million. This path, divesting non-core assets first, then reducing debt, then doing a small acquisition, and finally conducting limited buybacks, is more disciplined than many newly spun-off companies.

The real issue is not that "management is spending money recklessly," but that there is still not a long enough independent capital-allocation record to score with confidence. Therefore, my view on management and capital allocation is: the direction is right, but the evidence is not yet thick enough.

Management and Capital Allocation Score: 3/5.

Financial Quality

Start with the most important conclusion: Solventum's financial statements cannot be judged by GAAP net income alone. You have to separate out the pre-spin carve-out basis, the 2025 P&F sale, ongoing spin-off/restructuring costs, and short-term TSA income and expenses. Without doing this, you can reach completely opposite conclusions between "high profit" and "poor cash flow." In its 2024 10-K, the company clearly warned that pre-spin historical financial statements were prepared using carve-out methods and may not represent the future performance of the independent company.

Key Financial Metrics Table

The 2022-2025 revenue, operating profit, operating cash flow, capital expenditure, and free cash flow in the table above come from the company's 2024 and 2025 10-Ks; the 2026Q1 figures come from the Q1 2026 10-Q. Free cash flow in the table is my calculation using "operating cash flow minus capital expenditure"; note that 2022-2023 include pre-spin carve-out basis, while 2025 includes the P&F sale and spin-off costs, so comparability is not perfect.

How Should These Numbers Be Read? Looking only at revenue, Solventum resembles a stable company with "low-single-digit growth": revenue was basically flat from 2022 to 2025, moving from $8.130 billion to $8.325 billion. What really deteriorated is post-spin profit quality and cash-flow performance. GAAP operating margin fell from 20.6% in 2023 to 12.6% in 2024, mainly because of stock-based compensation, the initial build-out costs of independent operations, and debt interest; 2025 GAAP margin appeared to rise sharply to 26.2%, but this was mainly because of a $1.549 billion gain on business sale and cannot be treated as normal. In other words, the high profit in 2025 was not a natural reflection of better operations, but the result after one-off transactions made the numbers look better.

Using management's own basis that excludes one-off impacts, adjusted operating margin was 22.0% in 2024 and 20.5% in 2025; adjusted EPS was $6.11 in 2025, below $6.70 in 2024. This shows that after divesting P&F, although debt declined and the business became more focused, core earning power did not immediately become stronger.

Do Accounting Profit and Cash Flow Match? They basically matched in 2022-2024, especially in 2022-2023 when operating cash flow and free cash flow were both quite strong; but 2025-2026 entered an obvious mismatch phase. In 2025, net income reached $1.556 billion, but operating cash flow was only $369 million, and free cash flow was negative $10 million; in Q1 2026, net income was $13 million, operating cash flow was negative $189 million, and free cash flow was negative $273 million. This is not a typical fraud signal, but it means you must require proof that cash flow repair is happening, rather than only listening to adjusted EPS.

Is the Balance Sheet Stable? It is much more stable than immediately after the spin-off, but still not very relaxed. At year-end 2025, cash was $878 million and debt was $5.035 billion; by the end of Q1 2026, cash had fallen to $561 million, and total debt was about $5.080 billion, including short-term debt and current maturities of about $505 million. The company also has a $2.0 billion revolving credit facility, undrawn at year-end 2025, with no commercial-paper balance. Based on a rough estimate using 2025 adjusted EBITDA, net debt/adjusted EBITDA was around 2 times, which is manageable, but far from "zero pressure."

Are ROE and ROIC Excellent? They may look decent on the surface, but I do not recommend over-glorifying post-spin ROE/ROIC. The reason is that the spin-off left Solventum with significant debt and made book equity much thinner. Shareholders' equity was only $2.959 billion at year-end 2024 and only $5.049 billion at year-end 2025. Under this capital structure, any medium-level operating profit may look like "high ROE, high ROIC." Therefore, Solventum's ROIC can be referenced, but it should not be directly scored highly as if this were a mature company that had operated independently for ten years.

Are There Signs of Financial Fraud or Aggressive Accounting? I have not seen direct evidence of obvious financial fraud. The company's 2025 10-K received an unqualified audit opinion, and the company has a clawback policy and relatively complete governance structure. The real concern is not fabricated revenue, but "normalization of adjustments": the items used to calculate non-GAAP results in 2025 were numerous, including amortization, restructuring, 3M spin-off-related costs, litigation-related costs, P&F separation costs, disposal gains, debt-redemption losses, and acquisition-related expenses. For value investors, this type of company that adjusts every year should be assigned a default discount.

Owner Earnings and Intrinsic Value

Start with the conclusion: Solventum's "reported free cash flow" is weak, but "normalized owner earnings" may not be that poor; the problem is that the gap between the two is large, and you must decide which one you believe.

Factual Starting Point for Owner Earnings. In 2025, GAAP net income was $1.556 billion, including a $1.549 billion gain on business sale; operating cash flow was $369 million, and capital expenditure was $379 million; depreciation and amortization was $489 million, and stock-based compensation was $161 million. On the strictest basis, 2025 free cash flow was about negative $10 million, which clearly cannot represent the long-cycle earning power of a stable healthcare company.

Conservative Normalized Owner Earnings Estimate. I do not value the company directly using 2025 reported free cash flow, because that would clearly underestimate the company's cash-generation ability in a normal year; but I also do not want to fully capitalize 2025 adjusted EPS, because that would ignore ongoing spin-off friction, restructuring, and the risk that cash conversion falls short of expectations. A more conservative approach is to start with the midpoint of 2026 adjusted EPS guidance, about $6.50, and use about 173.5 million shares as of the end of March 2026, implying adjusted net income of about $1.13 billion; then discount the current stage based on management's target of reaching 80%+ free-cash-flow conversion only in 2028, assuming only a 65%-80% cash conversion rate. Normalized Owner Earnings would then be roughly in the $730 million-$900 million range. This range is clearly above 2025 reported free cash flow and clearly below the overly optimistic method of treating "adjusted profit = all distributable cash."

My Conservative Point Estimate: Owner Earnings of About $750 Million. This means the current market capitalization of $13.15 billion equals about 17.5 times conservative Owner Earnings; using enterprise value of about $17.67 billion, it equals about 23.6 times. For a company with a moderate moat, still in transition, and with real cash-flow recovery not yet proven, this valuation does not provide much room for error for a "conservative investor." Using a neutral estimate of $900 million in Owner Earnings, the current market capitalization equals about 14.6 times; using an optimistic estimate of $1.05 billion, it is about 12.5 times. So this is not an "obviously cheap" stock, but more like "not expensive if everything repairs smoothly; not cheap if repair disappoints."

Intrinsic Value Estimate

Method One: Owner Earnings Discounting The valuation below reflects my model assumptions, not company guidance.

The basis for these assumptions is that the company's 2026 adjusted EPS guidance is $6.40-$6.60, and its 2028 targets are 4%-5% organic growth, 23%-25% operating margin, 10% EPS CAGR, and 80%+ FCF conversion; but given uncertainty around spin-off execution, supply substitution, litigation, and software competition, I do not fully accept management's targets in the conservative and neutral scenarios.

Based on this, I give the following ranges: Conservative intrinsic value range: $50-$65; Reasonable intrinsic value range: $70-$90; Optimistic intrinsic value range: $105-$135. At the current share price of about $74.95, SOLV is roughly between the lower end and the middle of the reasonable range: not especially expensive, but far from the "obvious bargain" state I would want.

Method Two: Relative Valuation As of May 29, 2026, SOLV's GAAP trailing P/E was about 13.95 times; Becton Dickinson was about 37.3 times, GE HealthCare about 14.95 times, Medtronic about 20.6 times, and Dentsply Sirona was negative. Using year-end 2025/2026Q1 data as a rough calculation, SOLV's P/B was about 2.6 times; using 2025 adjusted EBITDA, EV/adjusted EBITDA was about 8 times. On the "apparent book multiple" basis, SOLV is indeed below many large medical-device peers. The problem is that most of those peers have longer independent operating records, more mature cash flows, and less spin-off noise, so you cannot infer that SOLV is cheap simply because they are more expensive. In my view, SOLV's low valuation largely reflects uncertainty, rather than a pure market mispricing.

Method Three: Asset and Liquidation Value This company is not suitable for using liquidation value as a floor. At year-end 2025, total assets were $14.294 billion, including $5.704 billion of goodwill and $2.592 billion of net intangible assets; at the end of Q1 2026, the two figures were still $5.626 billion and $2.497 billion, respectively. In other words, a large portion of Solventum's "book assets" comes from goodwill and intangible assets. On a year-end 2025 basis, tangible net assets were negative. This means it is not an asset-discount stock with "net cash plus land plus valuable inventory." Almost all of the real value rests on future operating cash flow. For conservative investors, this is very important: book assets will not provide much safety cushion.

Ideal Buy Price Range: $55-$65 This range roughly corresponds to my conservative value area, or a clearer discount to the lower end of the reasonable value range. If the share price returns here, balanced and conservative long-term investors would more easily have a buffer that says, "even if recovery is slower, permanent capital loss is less likely." At the current price, I would rather call it researchable and trackable, but not something to rush into with a heavy position.

Acceptable Holding Price Range: $65-$85 This is more suitable for investors who already hold shares passively through the 3M spin-off or established positions earlier. If the share price moves above $100, I would view it as clearly starting to price in too much of the neutral scenario, especially before cash flow has fully repaired. This range is a judgment-based view grounded in the DCF range above and the current quality of the fundamentals.

Margin of Safety and Key Risks

Is the Current Price Cheap Enough? My answer is: not cheap enough for comfort. If you believe management can largely deliver the 2028 growth, margin, and 80%+ FCF conversion targets, the current price is not expensive; but if you insist that "value investing must make money without relying on perfect execution," then the current price does not have enough room. For conservative investors, the real vulnerability is not the revenue forecast, but the cash-conversion assumption.

What Is the Most Vulnerable Valuation Assumption? It is not "whether demand will exist over the next 10 years," but the following three points: First, how long spin-off and restructuring expenses will take to fade; Second, whether gross margin will be permanently eroded after supply-chain migration away from 3M; Third, whether management's normalized FCF can actually be realized, instead of staying only at the non-GAAP level for a long time. The company's 2025 and 2026Q1 cash flows have already told us that recovery does not happen automatically.

If Growth Is Below Expectations, Does the Investment Still Work? If organic growth over many future years can only remain around 2%, rather than the 4%-5% in management's 2028 target, the investment may still work, but only if cash conversion repairs significantly and margins stop declining. Conversely, if growth is low and cash flow is also weak, the return implied by the current price will quickly sink into the mid- to low-single digits.

If Margins Decline and Valuation Multiples Contract, Could There Be Permanent Loss? Yes, and this is exactly what worries me most. Solventum is not an asset-cushion company; tangible net assets are negative, and the real support comes from future cash flow. If over the next two or three years the company proves to be just a pile of "mature assets with higher costs and worse cash conversion after leaving 3M," the market may keep its valuation center in the low teens or even lower. That would create the classic combination of "good industry, average company, ordinary price," with mediocre returns and even permanent capital loss.

Most Important Risks

Competitive Risk. The company operates across multiple highly competitive healthcare niches, with competitors including BD, Smith+Nephew, Coloplast, Convatec, Dentsply Sirona, Envista, Straumann, Align, Optum, Epic, Oracle/Cerner, Waystar, and others. It is not a monopolist, but a multi-front competitor.

Technology and Substitution Risk. The HIS business is especially exposed to competition from AI, speech, automated coding, and cloud platforms. The 10-K has explicitly identified AI and deployment of new technologies as important risks and opportunities.

Regulatory and Reimbursement Risk. Medical products and software are highly regulated, and changes in insurance reimbursement and value-based care rules can directly affect customer budgets, adoption, and pricing.

Supply-Chain and 3M Dependency Risk. This is one of the most substantive risks in this case. 3M remains the sole source for certain critical materials, and these materials involve products representing about $3.0 billion of revenue. If substitution progress is poor, quality validation is blocked, or costs rise, margins could be eroded for a long time.

Legal and Environmental Risk. The company currently bears Bair Hugger-related litigation management and indemnification responsibilities, while 3M remains one of the defendants in related litigation; at the same time, the boundaries of historical and future PFAS responsibility became more complex after 2025, especially for products that still contain PFAS components after 2025, because 3M's existing indemnification arrangements no longer automatically apply. The company itself disclosed that it cannot estimate the range of additional losses beyond recorded liabilities.

Valuation and Capital Allocation Risk. Buybacks are not bad in themselves, but in Q1 2026 the company began executing buybacks while free cash flow was negative, although the amount was only $67 million. If future cash-flow recovery is slower than expected and the company continues to use cash for buybacks or acquisitions, "apparent undervaluation" will become an "amplifier of capital-allocation mistakes."

The Strongest Bear Case. The strongest bear logic is this: Solventum is not an "undervalued high-quality compounder," but a "mature healthcare company exposed as a second-tier asset portfolio after leaving 3M." It looked high quality in the past partly because the 3M system provided brand, R&D, supply-chain, and cost support; once independent, true SG&A, tax, interest, IT, compliance, and supply-chain costs surfaced, and the prior high cash flow may no longer be sustainable. In addition, the company sold P&F, a relatively high-quality asset that improved margins and helped reduce debt. The remaining portfolio does not grow fast, competition is not easy, and the software business does not have strong platform network effects. Therefore, the market's low multiple is reasonable rather than cheap. This bear case is not absurd.

What Facts Would Overturn My Investment View? If the following facts appear, I would acknowledge that the current "Watch and wait" judgment needs to be revised more negatively: If by 2027, after spin-off costs have clearly stepped down, free cash flow is still below $400-$500 million for an extended period; If 3M supply-chain substitution causes gross margin/operating margin to keep deteriorating rather than recovering; If Bair Hugger/PFAS risk expands significantly and turns into quantifiable large cash payments; If HIS or MedSurg underperforms industry growth materially for several consecutive years. Conversely, if operating cash flow and FCF reverse clearly from the second half of 2026 to 2027, and buybacks and deleveraging continue to move forward with discipline, I would be willing to upgrade the rating.

Checklist and Final Investment Conclusion

Investment Checklist

The table above is my summary based on the facts and inferences in the full report, not company disclosure. The core reason is: understandability is higher than moat strength, business quality is higher than cash-flow certainty, and the current price does not provide enough room for error.

Comparison with Other Opportunities

Compared with the strongest peers, SOLV currently trades at a lower P/E than BD and MDT and close to GE HealthCare, but its independent operating record, cash-flow stability, and moat clarity are weaker than those mature platforms. Compared with the S&P 500, SOLV's nominal earnings yield is meaningfully higher; the S&P 500's current earnings yield is about 3.06%, while SOLV's earnings yield based on the midpoint of 2026 adjusted EPS guidance is about 8.7%. But compared with the 10-year U.S. Treasury at about 4.45% and Aaa corporate bonds at about 5.65%, SOLV's extra return compensation is not "risk-free." It requires you to bear execution, legal, and cash-flow repair risks at the same time. Therefore, buying it is not clearly superior to buying the index, nor clearly superior to buying high-grade bonds; if I could hold only 5 assets, SOLV does not yet qualify as a core portfolio position.

Final Investment Conclusion

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Solventum's underlying business is not poor, but it remains a spin-off company that has not yet validated its cash-flow and moat rebuild, and the current price does not offer enough margin of safety for conservative long-term investors.

【Core Bull Points】 The company is deeply rooted in necessary healthcare use cases, with long-term demand and diversified customers, and no single customer above 10%. The business mix includes some recurring revenue foundation, including HIS software deferred revenue and MedSurg equipment rentals. After divesting P&F, the assets are more focused, and the company significantly reduced debt in 2025, easing financial pressure versus the immediate post-spin period. Management's recent capital allocation has been broadly rational: sell non-core assets first, then reduce debt, then pursue cautious M&A and buybacks. If the 2028 LRP is largely achieved, the current market capitalization is not expensive.

【Core Bear Points】 Real free cash flow in 2025 and 2026Q1 was weak, showing that the risk of "good-looking profits but mediocre cash flow" is real. The company still deeply depends on 3M's supply chain and transition agreements, and separation carries execution and cost risks. Legal and PFAS risks have not fully cleared, and the upper bound of loss cannot be reliably estimated. Book tangible net assets are negative, so the balance sheet offers limited protection against valuation downside. Management's independent operating record is too short, and many "improvement stories" still remain at the target and roadmap stage.

【Key Assumptions】 Spin-off-related expenses will decline meaningfully over the next two years. 3M-related critical raw-material and manufacturing migration will be manageable and will not cause long-term gross-margin collapse. HIS and MedSurg organic growth can at least remain in the low- to mid-single digits. Major litigation and PFAS risks will not evolve into a very large cash drain.

【Fair Buy Price】 $55-$65 per share. This is based on a compromise between my conservative intrinsic value range of $50-$65 and reasonable value range of $70-$90: at this price, even if cash-flow recovery is slower than management hopes, there is still a greater probability of avoiding permanent capital loss. The current price of about $74.95 has not yet met this requirement.

【Target Holding Period】 If bought, it should be held for 5-10 years, rather than traded around quarterly volatility. The real validation window is 2026-2028: what you need to watch is cash flow, margins, and the 3M separation, not the short-term share price.

【Expected Annualized Return】 Conservative scenario: 4%-6%. Neutral scenario: 8%-11%. Optimistic scenario: 12%-15%. These are model-based estimates based on the Owner Earnings and multiple assumptions above, not market forecasts. The key support for these estimates is not revenue itself, but whether cash conversion recovers.

【Maximum Loss Risk】 If the company ultimately proves that normalized Owner Earnings are only around $400 million, and the market assigns only a 12 times equity valuation, then equity value may be only about $4.8 billion, implying a share price roughly in the $20s to $30s; if legal risk or supply-chain mistakes are added, downside could be larger. This scenario is not the current fact, but a stress-test inference based on the company's negative tangible assets and failed cash-flow repair.

【Tracking Indicators】 I suggest continuously tracking the following indicators: Organic revenue growth, especially in MedSurg and HIS. Adjusted operating margin and its pace of delivery. Operating cash flow and free cash flow, not just adjusted EPS. Quarterly changes in spin-off-related cash spending. 3M supply and manufacturing migration progress. Whether Bair Hugger / PFAS risk disclosures worsen. Net debt/EBITDA and interest-coverage levels. Whether buyback average price and pace remain restrained. Acera acquisition integration results. Whether disposal of 3M's remaining shareholding creates selling pressure.

【Signals That Trigger Reassessment】 Free-cash-flow recovery is clearly below management's path. The HIS software business is materially eroded by AI/large-platform competition. Post-spin cost and supply-chain issues become long-term rather than transitional. Legal and environmental liabilities expand significantly. Management pursues aggressive acquisitions or large buybacks before cash flow has repaired.

【Final Recommendation】 If you approach SOLV from the perspective of a "long-term business owner," my recommendation is: watch first, and do not rush in. This company deserves a place on the watchlist and continued tracking in 2026-2027, because its underlying business, industry position, and asset adjustment direction are not bad; but for balanced and conservative investors, what is needed now is "evidence," not a "story." Waiting until real free cash flow recovers, 3M separation risk declines, or the share price returns to a more obvious discount would look more like a Buffett-style investment than a bet on management execution.

Data Boundary and Basis Reminder: This report is based as much as possible on the company's latest 10-K, 10-Q, proxy statement, quarterly/annual earnings releases, and official/authoritative macro data. Special reminder: as a spin-off company that only became independently listed in 2024, Solventum has a very short independent operating history; much of the 2022-2024 data has carve-out characteristics, while 2025-2026 are affected by business disposal, restructuring, and transition agreements, so any valuation must accept a relatively wide error band. This is not an excuse of "insufficient information," but the objective reality of this company.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.